A3P

Log in

This guidance Describes and Explains the final rule on current Good Manufacturing Practice (CGMP) requirements for combination products That FDA Issued on January 22, 2013 (final rule).2 (21 Code of Federal Regulations (CFR) from 4). Prior to issuance of the final rule, ALTHOUGH CGMP règlements Were in place to suit les requirements for drugs, devices, biological products, and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT / Ps), There Were No règlements to Clarify and explain the implementation of These CGMP requirements to combination products. The final rule Did not suit les Any new requirements; It was Intended to Clarify qui CGMP requirements apply When drugs, devices, and biological products are combined to create combination products, and to set forth a transparent and streamlined Regulatory framework for firms to use When Demonstrating compliance with CGMP requirements applicable.

Section II of this paper Provides the definition of "combination product," an overview of the final rule, and Describes the role of the center and lead components --other Agency4 with respect to combination product CGMP issues. Section III addresses some general considerations for CGMP compliance for combination products. Section IV presents the purpose and content of CGMP specific requirements Addressed in the final rule. Finally, Section V Analyzes hypothetical scenarios That Illustrate how to comply-with CGMP requirements for some specific kinds of combination products. Throughout this guidance, the Agency aussi Refers to Existing guidance and additional resources That address CGMP requirements for drugs, devices, biological products, and HCT / Ps, to inform further Top combination product manufacturers on how to comply-with CGMP requirements.

.

Final Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P